Highest-materiality recent filing
Alpha Cognition settles Galantos royalty obligations for EUR 5.2M one-time payment, ~40% discount
Entered settlement agreement with Galantos Pharma to extinguish all future royalty and milestone obligations under the Memogain APA.
Alpha Cognition FY2025 revenue $10.2M, net loss $20.7M; ZUNVEYL bottles up 62% QoQ
FY2025 total revenue $10.2M: ZUNVEYL net product revenue $6.8M + licensing $3.4M.
Alpha Cognition prices $35M oversubscribed public offering at $6.25/share
Gross proceeds of ~$35M from 5.6M shares (incl. pre-funded warrants) at $6.25 per share.
Alpha Cognition closes $46.2M public offering of common shares and pre-funded warrants
Closed underwritten public offering of 8,695,653 common shares and/or pre-funded warrants for net proceeds of ~$46.15 million (or $52.48 million with full underwriter option).
Alpha Cognition approves 1:25 reverse stock split effective Nov 5, 2024 to meet Nasdaq minimum bid
Board approved 1-for-25 reverse split; authorized common shares reduced from ~150.9M to ~6.0M effective Nov 5, 2024.
Alpha Cognition shareholders approve quorum increase to 33-1/3% for Nasdaq listing at annual meeting
Quorum for shareholder meetings raised from 5% to 33-1/3% to satisfy Nasdaq Marketplace Rule 5620(c).
Alpha Cognition raises $4.545M via senior convertible notes and warrants
Issued $4,545,000 aggregate principal of senior convertible notes to accredited investors on Sept 24, 2024.
Alpha Cognition raises $4.545M via senior convertible notes and warrants
Gross proceeds of $4.545M from sale of senior convertible notes (10% interest, maturity Sept 2026) and warrants.
Alpha Cognition Q2 net loss $2.1M; FDA approves ZUNVEYL for Alzheimer's
Q2 2024 net loss $2.1M ($0.01/share) vs Q2 2023 net loss $2.8M ($0.03/share).
Alpha Cognition gets FDA approval for ZUNVEYL to treat mild-to-moderate Alzheimer's
FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease; second oral AD therapy approved this decade.
On April 7, 2025, the Board appointed Robert Wills, Ph.D., (“Dr. Wills”) to the Board and Governance and Nominating Committee, effective April 7, 2025.
On April 7, 2025, John Havens informed Alpha Cognition Inc. (the “Company’) of his intention not to run for re-election to the Board of Directors (the “Board”) of the Company at the Company’s annual meeting of stockholders in 2025.
On October 21, 2024, Mr. Jay Yoo tendered his resignation as interim Principal Accounting and Financial Officer of Alpha Cognition Inc. (the "Company"), effective October 21, 2024.
On October 21, 2024, the Company appointed Mr. Henry Du, age 46, to act as the Company's Vice President of Finance and Accounting and interim Chief Financial Officer effective October 21, 2024.
The Company previously announced the resignation of Mr. Don Kalkofen as Chief Financial Officer on August 27, 2024, effective October 1, 2024.
On October 8, 2024, Alpha Cognition Inc. (the “Company”) appointed Mr. Jay Yoo to act as the Company’s interim Principal Accounting and Financial Officer effective October 2, 2024.
On August 21, 2024, Mr. Don Kalkofen tendered his resignation as Chief Financial Officer of Alpha Cognition Inc. (the “Company”), effective October 1, 2024.
Max materiality 0.90 · Median 0.50 · Most common event other_material